Seres Therapeutics, Inc. (NASDAQ: MCRB) had its "buy" rating re-affirmed by analysts at Canaccord Genuity Group Inc.. They now have a $10.00 price target on the stock.
Seres Therapeutics Inc (MCRB) Q3 2024 Earnings Call Highlights: Strategic Moves and Clinical ... [Yahoo! Finance]
Seres Therapeutics, Inc. (NASDAQ: MCRB) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $1.25 price target on the stock.
Seres Therapeutics, Inc. (MCRB) Q3 2024 Earnings Call Transcript [Seeking Alpha]
Seres Therapeutics GAAP EPS of -$0.33 misses by $0.25 Nov. 13, 2024 7:05 AM ET By: Deepa Sarvaiya , SA News Editor [Seeking Alpha]